Patents by Inventor John L. Gilmore

John L. Gilmore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulators of the glucocorticoid receptor, AP-1, and/or NF-?B activity and use thereof
    Patent number: 7569689
    Abstract: A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR1R2 or CH2NR1R2 and where at least two of X1-X4 and/or X5-X8 is N or NR18, and R, Ra, Rb, Rc, Rd, R1, R2 and R18 are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
    Type: Grant
    Filed: January 13, 2005
    Date of Patent: August 4, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jingwu Duan, Bin Jiang, James Sheppeck, John L. Gilmore
  • Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-?B activity and use thereof
    Patent number: 7544808
    Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein B, J, K, Z, R, Ra, Rb, Rc, Rd, Rq, Rw, m and n are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: June 9, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: David S. Weinstein, John L. Gilmore, James Sheppeck, Bingwei Vera Yang, Soong-Hoon Kim, Wayne Vaccaro
  • Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-?B activity and use thereof
    Patent number: 7253283
    Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein B, J, K, Z, R, Ra, Rb, Rc, Rd, Rq, Rw, m and n are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
    Type: Grant
    Filed: January 13, 2005
    Date of Patent: August 7, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: David S. Weinstein, John L. Gilmore, James Sheppeck, Bingwei Vera Yang, Soong-Hoon Kim, Wayne Vaccaro
  • Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-? converting enzyme (TACE)
    Patent number: 7211671
    Abstract: The present invention describes novel 1,3-dihydro-imidazol-2-one or 1,3-dihydro-imidazol-2-thione compounds of formula (I): or a stereoisomer or pharmaceutically acceptable salt or solvate thereof, wherein A, L R1, R2, R3 and R4 are defined in the present specification, which are useful as selective inhibitors of MMP, TACE, aggrecanase or a combination thereof. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.
    Type: Grant
    Filed: September 21, 2004
    Date of Patent: May 1, 2007
    Assignee: Bristol Myers Squibb Company
    Inventors: James Sheppeck, John L. Gilmore, Xiao-Tao Chen, Xiaohua He
  • Triazolone and triazolethione derivatives as inhibitors of matrix metalloproteinases and/or TNF-? converting enzyme
    Patent number: 7074810
    Abstract: The present application describes novel hydantoin derivatives of formula (I): or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, L, and R11 are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-? converting enzyme (TACE), aggrecanase, or a combination thereof.
    Type: Grant
    Filed: October 3, 2003
    Date of Patent: July 11, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Bryan W. King, James Sheppeck, John L. Gilmore
  • Triazolone and triazolethione derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme
    Publication number: 20040116491
    Abstract: The present application describes novel hydantoin derivatives of formula (I): 1
    Type: Application
    Filed: October 3, 2003
    Publication date: June 17, 2004
    Inventors: Bryan W. King, James Sheppeck, John L. Gilmore
  • Method of imaging amyloid deposits
    Patent number: 6001331
    Abstract: The present invention provides a method of imaging amyloid deposits and radiolabeled compounds useful in imaging amyloid deposits. The invention also provides a method of delivering a therapeutic agent to amyloid deposits, a method of inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of determining a compound's ability to inhibit aggregation of amyloid proteins.
    Type: Grant
    Filed: July 22, 1998
    Date of Patent: December 14, 1999
    Assignee: Warner-Lambert Company
    Inventors: Bradley W. Caprathe, John L. Gilmore, Sheryl J. Hays, Juan C. Jaen, Harry LeVine, III